logo-loader
Aphria

Aphria expands Latin American medical cannabis presence with entry into Paraguay

President Jakob Ripshtein said Aphria will continue to “expand its footprint” in the most strategic markets in Latin America

A medical researcher holding up a cannabis plant and CBD oil
The company is involved in the low-cost production of safe, clean and pure pharmaceutical-grade cannabis

Canadian cannabis company Aphria Inc (TSX:APH) (OTCQB:APHQF) said Wednesday that it has signed a Letter of Intent with Paraguayan pharma company Insumos Medicos SA, for the exclusive supply and distribution of medical cannabis in Paraguay.

“Latin America continues to represent an important growth opportunity within the global medical cannabis industry, and we are excited to be among the first to enter the rapidly emerging market in Paraguay,” said Aphria president Jakob Ripshtein.

READ: Aphria forms special committee to review its Latin American acquisitions

“Our strategic partner, Insumos, is well-positioned to establish a leading presence for the company’s products throughout the country,” he added.

In September, Aphria closed the acquisition of LATAM Holdings Inc from Scythian Biosciences (CSE:SCYB).

On Wednesday, the company backed its Latin American operations and strategy and reiterated its confidence in the process leading to its C$280 million worth of Latin American acquisitions.

“Aphria will continue to expand its footprint in the most strategic markets in Latin America and around the world through its diversified approach to innovation, partnerships and expansion,” emphasized Ripshtein.

Aphria has supply agreements with every province in Canada and the Yukon Territory, ensuring access to Aphria products for 99.8% of the Canadian population. It has launched a large portfolio of adult-use brands: Solei Sungrown Cannabis, RIFF, Good Supply, and Goodfields.

The stock was up nearly 4%  in premarket trade Wednesday but pared its gains after the bell to $11.57 in the OTC Markets.

 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Aphria

Price: $8.15

Market: TSX
Market Cap: $2.05 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights licenses electronic data capture software to UK...

CB2 Insights (CSE:CBII-OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from Proactive Vancouver to discuss the company doing a deal with MYACCESS Clinics. This will allow CB2’s software to capture comprehensive data sets related to patient health and treatment histories and manage ongoing...

11 hours, 21 minutes ago

2 min read